A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of bowel cancer received pembrolizumab for up to nine weeks before surgery instead of the usual post-surgery chemotherapy. After nearly three years of follow-up, none of the patients had experienced a cancer recurrence, including those who still had small traces of disease after treatment.
More in Research
Mysterious brain activity under anesthesia challenges what we know about consciousness
October 15, 2026
Arctic sea ice hits another troubling low in 2026
October 15, 2026
Eating late at night linked to up to 30% higher risk of liver disease
October 15, 2026
A fungus is threatening the world’s food supply. Scientists just found a new defense
October 15, 2026
Scientists discover a surprising danger in smaller cancer cells
October 15, 2026
Rare study reveals a striking divide inside an Alzheimer’s patient’s brain
October 15, 2026
Latest News
சௌதியில் மரண தண்டனை ரத்தான சிவராசா அனோஜனுக்கு அடுத்தது என்ன? இலங்கை அரசு தரப்பு புதிய தகவல்
October 16, 2026
Inside Ukrainian offensive pushing Russia back on front line where Starlink plays a key role
October 16, 2026
Zelensky says Ukraine has right to defend itself after Trump calls latest strikes a 'disgrace'
October 16, 2026
Watch: Will Ukraine get the support needed as tensions with US rise?
October 16, 2026
நேஹா போரா தடுத்து வைப்பு: அபிஜித் தீப்கே எங்கே? டெல்லி காவல்துறையிடம் சிஜேபி கேள்வி
October 16, 2026
‘Batman’ Writer Matt Fraction On The Impending Assassination Of Bruce Wayne
October 16, 2026